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Abstract: Osteoporosis is a significant concern for postmenopausal women and is a critical factor in hip fracture. Examining evidence 
for osteoporosis medications in hip fracture is important for optimizing treatment.
Purpose: Review risedronate’s role for hip fracture in postmenopausal women.
Methods: A literature search was conducted using Medline and Web of Science. The search was limited using the terms “risedronate” 
and “hip fracture,” and to studies that included women. Similar articles linked to the search and pertinent articles in bibliographies were 
also examined.
Results: Risedronate has demonstrated efficacy and cost effectiveness for hip fracture, but may not be beneficial for patients with low 
fracture risk. Risedronate is generally well tolerated, but may cause side effects in some patient populations.
Conclusion: Risedronate has benefit for hip fracture, but patients should be carefully screened to determine the appropriateness of 
risedronate before starting treatment.
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Introduction
Osteoporotic fractures are a common problem, with 
an estimated 9 million that occurred worldwide in 
2000.1  Among  these,  hip  fractures  have  received 
substantial attention because of their potential effect 
on quality of life. There were 1.66 million hip frac-
tures worldwide in 1990, but it has been estimated 
that 6.26   million fractures will occur annually world-
wide by 2050 assuming the rate of hip fracture does 
not  decline.2  Interestingly,  research  has  indicated 
that non-hip fractures contribute to greater morbid-
ity than hip fractures up to the age of 75.3 Hip frac-
tures are important because they have been associated 
with mortality, but the direct impact on mortality has 
been difficult to quantify because of the high rate 
of  co-morbidities  in  patients  who  experience  hip 
fractures.4,5  Together,  these  data  indicate  that  hip 
fractures  become  an  increasingly  important  health 
concern as people age and develop a greater num-
ber of co-morbidities.   Postmenopausal women rep-
resent a group at high risk for osteoporosis, and the 
rise in hip fracture burden with increasing age was 
supported by a study in Australia in postmenopausal 
women that estimated the 5-year risk of hip fracture.6 
This analysis utilized a Markov process with Monte 
Carlo simulations and found that the risk of hip frac-
ture  increased  substantially  for  the  oldest  patients. 
For instance, patients aged 75–79 had a 5-year risk 
for first hip fracture of 3.8%, while those aged 90 and 
older had a 20.9% risk. Hip fracture clearly presents 
a problem for aging, and evaluating medications to 
weigh their benefit and potential risk in older women 
with greater co-morbidities is therefore important.
Bisphosphonates have become a mainstay in treat-
ing  and  preventing  osteoporosis,  and  studies  with 
these agents have shown that they are more effective 
at reducing vertebral fractures than hip fractures. For 
example, in the pivotal BONE trial for ibandronate, 
there  was  not  a  statistically  significant  benefit  for 
non vertebral fracture.7 However, even the bispho-
sphonates which have shown significant benefit for 
hip fracture require a larger number needed to treat 
(NNT)  to  prevent  one  hip  fracture  than  is  neces-
sary to prevent one vertebral fracture. Therefore, a 
closer examination of the data for bisphosphonates 
specific to hip fracture is important to better charac-
terize which patients will receive benefit from these 
medications.  This  article  focuses  on  risedronate, 
which has received interest because its cyclical side 
chain (compared to alendronate’s amino side chain) 
may improve its gastrointestinal tolerability. Studies 
reviewed include those assessing risedronate’s impact 
and cost for hip fracture in post menopausal women 
as well as those examining available safety data.
Mechanism of Action
Risedronate  is  classified  as  a  nitrogen-containing 
  bisphosphonate.  Bisphosphonates  exert  their  effect 
by inhibiting bone resorption that normally occurs 
in the body during the bone remodeling process. Part 
of this effect is exerted through binding to hydroxy-
apatite crystals within bone matrices, which prevents 
both calcification and breakdown of hydroxyapatite 
and in turn reduces bone resorption.8,9 In addition, 
  osteoclasts, the cells responsible for breaking down 
bone  during  the  remodeling  process,  also  ingest 
  bisphosphonates  through  endocytosis.  Once  inside 
the osteoclast, nitrogen-containing bisphosphonates 
such  as  risedronate  interfere  with  the  intracellular 
mevalonate pathway, which in turn inhibits the produc-
tion of   sterols, cholesterols, and lipids.10,11   Interference 
with this pathway affects post-  translational modifi-
cation of key cellular proteins, which subsequently 
alters   regulation of osteoclast activity and may result 
in osteoclast apoptosis.12
pharmacokinetics and Metabolism
Risedronate,  like  other  bisphosphonates,  is  poorly 
absorbed  from  the  digestive  tract.  For  instance, 
the  mean  bioavailability  of  the  30  mg  tablets  is 
0.63%.13 Taking the medication with food can fur-
ther  affect  absorption;  therefore,  the  medication  is 
recommended to be administered 30 minutes before 
breakfast.   Risedronate is not metabolized, and any 
risedronate that is not absorbed from the digestive 
tract  is  excreted  unchanged  in  the  feces. Approxi-
mately 60% of the dose absorbed is adsorbed by the 
bone, and the remainder is excreted unchanged by 
the kindey.13 Steady state is reached by 57 days after 
starting    treatment.  In  post-menopausal  women  the 
half-life was found to be 561 hours.13
clinical studies
A Cochrane review pooled data from 7 risedronate 
studies to evaluate its impact on fracture in postmeno-
pausal women.14 This review found an NNT of 100 to risedronate for hip fracture
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prevent one hip fracture. However, this analysis also 
concluded that risedronate may not prevent hip frac-
tures in patients who do not have low bone density or 
a previous vertebral fracture. Therefore, it is impor-
tant to examine risedronate’s data in different patient 
groups to evaluate the benefit of risedronate when a 
patient’s risk factors are specifically considered.
For  hip  fracture,  the  Cochrane  review  included 
data from one small primary prevention trial in which 
no  patients  in  either  group  experienced  a  hip  frac-
ture as well as three trials for secondary prevention 
of  hip  fracture. Two  of  the  secondary  studies  were 
part of the VERT trial, which was published as sepa-
rate analyses, one from North America and the other 
from   Australia  and  Europe.15,16  Both  studies  used  a 
randomized, double-blind, placebo-controlled design, 
and patients received 2.5 mg risedronate, 5 mg rise-
dronate, or placebo daily for 3 years. However, the 
2.5 mg arm was stopped early because of lack of effi-
cacy in other risedronate studies. Enrollment criteria 
included being age 85 years or younger and 5 or more 
years post-  menopause, and having either 2 or more 
radiographically identified vertebral fractures or one 
vertebral fracture and a T-score #−2. Patients were not 
excluded for a history of gastrointestinal (GI) events but 
were excluded for recent use of drugs affecting bone 
 m e tabolism. In the VERT-North America trial, patients 
were similar with regard to baseline characteristics, 
which included smoking status, height, and weight.15 
In the international VERT trial patients were also con-
sidered to be similar, and height was included as a risk 
factor.16 The VERT-North America trial used vertebral 
fractures as the primary outcome.15 Non-vertebral frac-
tures were measured, but hip and pelvis fractures were 
reported together as one outcome, preventing an exact 
determination of risedronate’s impact on hip fracture. 
Using this combined outcome, 12 patients in the rise-
dronate  group  and  15  in  the  placebo  group  experi-
enced an event. However, statistical significance was 
not reported. In the international VERT trial, hip frac-
ture was reported separately (11 out of 406 in placebo 
group vs 9 out of 406 in the   risedronate 5 mg group 
over a 3 year period).16 However, statistical signifi-
cance was not provided. In an extension of this study 
in which 105 women taking placebo and 115 women 
taking risedronate 5 mg completed the extension, no 
new hip fractures occurred in either group during the 
additional 2 years of treatment.17
The final secondary prevention trial included in 
the Cochrane analysis, the largest trial studying rise-
dronate for hip fracture, was the Hip Intervention 
Program  (HIP).  HIP  focused  on  postmenopausal 
women  70  years  and  older.18  Patients  receiv-
ing  risedronate  were  divided  into  2  groups.  The 
first group included 70–79 year old women with a 
T-score ,−4.0, or a T-score ,−3.0 and at least 1 risk 
factor for hip fracture; the second group included 
patients $80 years old who met one of the follow-
ing criteria: $1 clinical risk factor for hip fracture, 
a hip T-score of ,−4.0, or a femoral neck T-score 
of ,−3.0 along with a hip axis length of $11.1 cm. 
Patients  in  the  $80  years  old  group  were  not 
required to have a bone density available, and the 
majority were enrolled based on a single clinical 
risk factor for hip fracture. Patients were excluded 
for any major medical illness, abnormal lab results, 
and recent use of medications that affect bone, but 
they were not excluded for GI issues. Patients were 
similar at baseline between groups, and other risk 
factors recorded included height, weight, and serum 
25-hydroxyvitamin D levels. Patients were treated 
for  3  years  with  2.5  mg  risedronate  daily,  5  mg 
  risedronate daily, or placebo. A total of 3624 rise-
dronate  patients  and  1821  placebo  patients  were 
enrolled in the 70–79 group while 2573 risedronate 
and 1313 placebo patients were enrolled in the $80 
year group. The average age was 74 for the 70–79 
year old group and 83 for the $80 year old group, 
and 98% of the patients were Caucasian. In the final 
analysis, patients taking the 2.5 mg and 5 mg doses 
were  combined  into  one  group  and  compared  to 
placebo. In the 70–79 year old group, an absolute 
risk reduction (ARR) in hip fracture of 1.3% was 
observed, giving an NNT of 77 (P = 0.009). A suba-
nalysis of patients in this group with known vertebral 
fracture at baseline had an ARR of 3.4% for hip frac-
ture vs. placebo (NNT = 29, P = 0.003). In the $80 
year old group no significant differences were found 
between  risedronate  and  placebo.  However,  the 
study authors noted that there was a potentially low 
rate of osteoporosis in this group. Since the majority 
of patients enrolled in this group qualified based on 
clinical risk factors, it is possible that many patients 
would not have qualified based on bone density cri-
teria. Data specifically for patients in this group who 
had a T-score available were not provided.Gates and Das
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A post-hoc analysis of the HIP trial combined the 
70–79 and $80 year old groups but included only 
those  patients  who  had  confirmed  osteoporosis,  as 
defined by a baseline femoral neck T-score #−2.5 
and 1 or more prior vertebral fracture(s).19 Using these 
criteria, 1656 women (1090 who received risedronate 
and 566 who received placebo) from the intent to treat 
population were included in the analysis. Over the 
3 year treatment period, in the placebo group 7.4% 
of the women experienced a hip fracture compared to 
3.8% of the women who took risedronate (ARR 3.6%, 
NNT = 28, 95% Confidence Interval [CI] 0.32–0.91, 
P = 0.019). Therefore, the data indicates that patient 
risk plays an important role in whether treatment with 
risedronate will provide benefit.
In order to further examine the effect of risedronate 
on the oldest patients who may be candidates for its 
use, an analysis was conducted that pooled data from 
the HIP and VERT trials for patients $80 years.20 
Pooling this data offered further insight into older 
patients  with  higher  risk  for  fracture  because  the 
VERT trial required a higher degree of risk for enrol-
ment  than  patients  entering  the  $80  years  of  age 
group  in  the  HIP  trial.  In  this  combined  analysis, 
704 patients received treatment with risedronate and 
688 received placebo. The mean age for both groups 
was 83. Though benefit was found for vertebral frac-
tures, there was still no benefit of risedronate on non-
vertebral fractures.
Additional  studies  by  Sato  and  colleagues  not 
included  in  the  Cochrane  analysis  observed  rise-
dronate’s impact on hip fracture in specific patient pop-
ulations in Japan at higher risk for fracture. One study 
focused on older women after stroke.21 Patients were 
at least 65 years of age (mean age 71.6 for   placebo and 
71.2 for risedronate) and were randomized to either 
2.5 mg of risedronate daily or placebo for 1 year. 
Patients were excluded if they had taken any medi-
cations that could affect bone metabolism (including 
vitamin D) and were also excluded for renal insuffi-
ciency, hepatic disease, and cardiac   failure. The BMD 
was taken from metacarpal measurements, was simi-
lar between groups, and was within the normal range. 
Each study group began with 187 patients, and 173 
patients in the risedronate group and 172 in the   placebo 
group completed the study. The two groups were con-
sidered  were  similar  for  demographic  information, 
including baseline   measurements of bone turnover. 
A hip fracture occurred in 7 of the 173 patients in 
the placebo group and in 1 of the 172 risedronate 
treated patients, (ARR = 3.4%, NNT = 29 for those 
completing the study, P = 0.036). Though statistical 
significance was not reported, patients taking placebo 
experienced greater loss of BMD on the hemiplegic 
side than on the unaffected side (4.9% compared to 
2.4%), compared with a 1.5% gain in BMD on the 
hemiplegic side in the risedronate group.
In another study by Sato et al., risedronate was 
given to patients who had been diagnosed with demen-
tia and probable Alzheimer’s Disease.22 Patients were 
required  to  be  70  or  older  and  were  followed  for 
18 months. Patients were excluded for a known cause 
of  osteoporosis  (such  as  renal  osteodystrophy),  as 
well as for use of a medication affecting bone metab-
olism for 3 months or longer in the 12 months prior 
to enrollment. Both the placebo and treatment groups 
enrolled 250 patients. The two groups were similar 
at baseline, including factors such as BMI, calcium 
and vitamin D intake, and falls prior to study entry. 
All patients were given 1000 IU of ergocalciferol and 
1200 mg of elemental calcium daily. The treatment 
group also received 2.5 mg of risedronate once daily. 
Patients  received  treatment  and  were  followed  for 
18 months. Evaluation of BMD was done by meta-
carpal measurement. Both groups had lower BMD 
than the reference for the normal Japanese popula-
tion, but statistical significance was not provided. In 
the risedronate group, 231 patients completed the trial 
compared with 230 in the placebo group. The study 
utilized an intention-to-treat analysis, and 5 patients 
in the risedronate group and 19 patients in the placebo 
group experienced a hip fracture with 18 months of 
treatment  (ARR  5.6%,  NNT  =  18,  P  ,  0.001). 
Though these trials are small, they provide interesting 
evidence because of the low NNT with use of 2.5 mg 
of risedronate, which is generally not considered to 
be an effective treatment dose.
Though the trials with risedronate discussed above 
lasted up to 3 years, an analysis of risedronate trials 
by Harrington et al. found a statistically significant 
reduction in non-vertebral fractures after 6 months 
of risedronate treatment. However, because hip frac-
tures  were  less  frequent  in  the  studies  than  other 
non-  vertebral fractures, such as those of the wrist, a 
specific analysis of hip fractures was not provided. 
Therefore, it is difficult to determine if risedronate can risedronate for hip fracture
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significantly reduce hip fractures with only 6 months 
of treatment.23
Head-to-Head studies
Direct comparisons of the bisphosphonates are of 
interest to determine which is the most   effective. 
However,  there  are  a  limited  number  of  these 
  studies, and those available either are retrospective 
analyses or compared BMD only rather than frac-
ture rate. A prospective head-to-head study, FACT, 
compared  1053  postmenopausal  women  treated 
for one year with either 70 mg alendronate weekly 
or 35 mg of risedronate weekly.24 This study mea-
sured BMD changes and changes in bone markers. 
  Significantly more patients treated with alendronate 
than risedronate achieved gains in BMD at various 
sites  while  significantly  more  risedronate  patients 
experienced  bone  loss  at  those  same  sites.  How-
ever, comparisons between agents can be difficult 
based  only  on  BMD  and  bone  turnover  markers. 
For  example,  an  analysis  examined  the  correla-
tion between bone density and non-vertebral frac-
ture using a COX regression model and data from 
both VERT studies and the HIP trial.25 This analysis 
found that changes in lumbar BMD explained only 
12% of risedronate’s effect on non-vertebral fracture 
risk (95% CI 2%, 21%, P = 0.014), and changes in 
femoral neck BMD explained only 7% of the effect 
on non-vertebral fracture risk (95% CI 2%, 13%, 
P = 0.005).   Therefore, differences in BMD may not 
necessarily indicate a change in fracture risk.
Retrospective analyses have also been completed 
to  attempt  to  compare  fracture  rates  based  on  use 
in clinical practice. A retrospective study of 41,135 
records  from  Medicare  beneficiaries  compared  the 
fracture  rates  associated  with  various  osteoporosis 
treatments after one year of treatment.26 This analysis 
found no difference in hip fracture rate between alen-
dronate and risedronate for up to 2 years after treat-
ment initiation (hazard ratio for taking risedronate 
0.92, 95% CI 0.70 to 1.20).
Another  retrospective  analysis,  REAL,  com-
pared  data  from  21,615  women  aged  65  and  over 
taking  once-weekly  alendronate  and  12,215  taking 
once-weekly  risedronate.27  Risedronate  had  a  sig-
nificantly lower risk of hip fractures, but to prevent 
one additional hip fracture taking risedronate com-
pared to alendronate, the NNT was 476 (P = 0.01). 
A   potentially   complicating factor is that alendronate 
35  mg  weekly,  which  is  used  for  prevention,  and 
70  mg  weekly,  which  is  used  for  treatment,  were 
combined into one group and compared directly with 
35 mg of risedronate weekly, which is used for both 
prevention and treatment.
The  retrospective  REALITY  analysis  also  used 
a large healthcare database to compare the effects of 
alendronate and risedronate on fractures.28 The analysis 
included women 65 years and older and utilized records 
of  12,956  patients  taking  treatment  doses  of  alen-
dronate and 6107 taking treatment doses of   risedronate. 
  Statistics  were  performed  using  a  Cox  proportional 
hazards model. This analysis found that patients tak-
ing   risedronate had approximately one additional frac-
ture for every 200 patient years of treatment compared 
to  alendronate  (relative  risk  [RR]  1.77,  1.15–2.74, 
P = 0.01), even though the overall fracture risk was 
similar between the two groups. A complicating fac-
tor that will be discussed later in the paper is that full 
records  could  not  be  completed  for  the  majority  of 
patients because of poor medication adherence.
Jansen et al., conducted a Bayesian network meta-
analysis  of  the  bisphosphonates  to  determine  the 
probability that one of the bisphosphonates would be 
more effective in preventing fracture.29 This analysis 
concluded that ibandronate had a 47% probability of 
having the greatest reduction in fracture risk, while 
alendronate had a 36% probability and risedronate 
had an 11% probability of having the lowest risk. 
This analysis looked at all fractures; therefore, it is 
difficult to directly determine a comparative effect on 
hip fracture, especially considering that ibandronate’s 
effect on hip fracture in the BONE trial did not reach 
statistical significance.
A  meta-analysis  by  Liberman  et  al.,  comparing 
different treatments for osteoporosis concluded that 
alendronate may be more effective than other osteo-
porosis treatments for reducing fractures.30 However, 
the  meta-analysis  compared  relative  risk  reduction 
among the agents. With the different initial designs 
for various trials, it can be difficult to make deci-
sions based on relative risk. For instance, this meta-
  analysis found the relative risk reduction (RRR) for 
hip fracture was 55% when taking alendronate com-
pared to placebo, while the RRR was 26% when tak-
ing risedronate. This RRR for alendronate matched 
the RRR for hip fracture found in the FIT trial, which Gates and Das
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was one of the largest studies involving alendronate. 
The FIT trial had an ARR of 1.1% for hip fracture, 
giving an NNT of 90. For comparison, the Cochrane 
review of risedronate for hip fracture found an NNT 
of 100, and the NNT was 77 for the 70–79 year old 
group in the HIP trial with risedronate. Therefore, 
comparisons across trials must be made carefully, and 
RRR alone may not be a reliable barometer to use for 
comparison.
A  systematic  review  of  trials  with  osteoporosis 
treatments found that that there was good evidence 
that alendronate, risedronate, and estrogen are more 
likely than placebo to prevent hip fractures and that 
there is fair evidence that zoledronic acid prevents 
hip fracture more than placebo.31 However, the study 
authors also concluded that there is insufficient evi-
dence to determine the relative efficacy and safety of 
the treatments.31
Cost effectiveness for hip fracture
With the varying NNT found for patients at different 
risk levels for fracture, evaluating risk before initiat-
ing treatment may help to avoid unnecessary medi-
cal costs. For instance, in the HIP study’s 70–79 year 
old group without a vertebral fracture, the NNT of 77 
for 3 years indicates that 231 patient years of treat-
ment would be required to prevent one hip fracture. 
In contrast, the HIP study’s 70–79 group with a pre-
vious vertebral fracture would have a substantially 
smaller cost with an NNT of 29, giving 87 patient 
years of treatment to prevent one fracture.   Currently, 
  risedronate  costs  over  $1200.00  per  year  in  the 
United States. Therefore, preventing one hip fracture 
could be very expensive depending on the medica-
tion costs in a given country. However, the cost of 
treating a hip fracture and the impact of fracture on 
the patient’s quality of life must also be considered in 
a cost-effectiveness analysis, and some studies have 
provided a deeper analysis into the cost effectiveness 
of   risedronate for hip fracture.
An analysis using a Markov model evaluated the 
cost of osteoporosis treatments for fracture for patients 
in Germany.32 This model assumed 3 years of treat-
ment with medication and calculated the cost to pre-
vent fracture over a 10 year time period.   Risedronate 
and  alendronate  were  the  only  medications  with 
  sufficient data to be included in the analysis for hip 
fracture, and this study determined that preventing 
one hip fracture with risedronate cost 37,348 euro 
compared to 48,349 euro for alendronate. The cost 
per quality adjusted life year (QALY) gained with 
risedronate was 32,092 euro while for alendronate 
the cost per QALY was 41,302 euro. The costs cal-
culated in this analysis were based on 2004 data, and   
the current availability of generic alendronate could 
alter this comparison. However, analyses based on 
costs in Canada and Italy using efficacy data from 
the  REAL  study  found  brand-name  risedronate  to 
be more cost effective than generic alendronate.33,34 
These studies also included other fracture types in the 
costs analysis; therefore, an exact comparison of hip 
fracture cost cannot be extrapolated. In addition, use 
of a different study as the basis for efficacy, such as 
the REALITY study that found greater efficacy for 
alendronate for hip fracture,28 could give a different 
cost effectiveness outcome.
A recent cost-effective analysis compared deno-
sumab  to  risedronate  and  alendronate  in  post-
menopausal  women  $60  years  meeting  criteria 
for  osteoporosis  in  Belgium.35  This  analysis  con-
cluded that denosumab was more cost effective than 
both  branded  risedronate  and  generic  alendronate. 
  However, this model assumed a 46% lower discon-
tinuation  rate  in  denosumab  patients  compared  to 
bisphosphonates that would need verification in prac-
tice to ensure that patients visited their provider in a 
timely manner to have this administered. This model 
also included data for vertebral, hip, and other non-
vertebral fractures, making a direct comparison of hip 
fracture cost effectiveness difficult.
One study provided guidance for initiating treat-
ment  by  calculating  the  10-year  hip  fracture  risk 
threshold that would be necessary for bisphosphonate 
use to be cost effective for hip fracture in the United 
States.36  This  analysis  utilized  a  Markov-cohort 
model with 2005 healthcare costs and assumed an 
annual bisphosphonate cost of $600.00 (US). Cost-
effectiveness was set at $60,000 per quality adjusted 
life  year  gained.  Using  these  criteria,  bisphospho-
nate treatment was effective when the 10-year hip 
fracture risk was 3% or higher. Since this analysis 
was done specifically for the United States, the cost-
  effective threshold could vary depending upon actual 
costs of risedronate and medical treatment in other 
  countries.  Even  within  the  United  States,  the  cur-
rent cost of risedronate is approximately twice the risedronate for hip fracture
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  estimated cost in this example and clinical judgment 
is therefore needed.
The 10-year fracture risk threshold was calcu-
lated in this study because it was designed to be 
used with the World Health Organization (WHO)’s 
FRAX tool. The FRAX tool was developed to help 
clinicians better determine absolute fracture risk.37 
FRAX calculates the 10-year fracture risk for both 
a  major  osteoporotic  fracture  and  a  hip  fracture 
based on data from 12 questions and a BMD test 
if it is available. Clinical judgment is still neces-
sary because of the variability of some factors. For 
instance, a female patient who is 80 years old, has 
a normal BMI, has no clinical risk factors, but does 
not have a BMD available is considered to have a 
10-year fracture risk above the 3% cost effective-
ness  threshold  and  therefore  would  be  recom-
mended for treatment. However, data from the HIP 
trial (whose patients had to have at least one clini-
cal risk factor to be entered rather than no factors 
like this sample patient) indicates that the sample 
patient would not receive benefit from   risedronate. 
However, if a normal BMD is also included in the 
FRAX analysis, the patient no longer meets the cost 
effectiveness threshold. Therefore, a BMD is impor-
tant in determining if treatment would be cost effec-
tive. Another consideration for FRAX is whether the 
patient’s expected lifespan may be shorter than the 
10-year time horizon. If other medical conditions 
may shorten the patient’s lifespan, the likelihood of 
fracture determined by FRAX can be adjusted pro-
portionately. For instance, if FRAX determined a 
patient had a 10% likelihood of hip fracture, the one 
year risk would be one-tenth of this value, or 1%.37 
The FRAX tool is available online at http://www.
shef.ac.uk/FRAX/  and  is  also  available  as  paper 
charts that can be downloaded from the site.
Risedronate safety
The Cochrane Review studying risedronate for hip 
fracture determined that there is imprecise informa-
tion available to make judgments regarding the risk 
of adverse effects from risedronate, especially for 
rare side effects such as osteonecrosis of the jaw.14 
However,  the  Cochrane  review  was  completed 
based on trials to assess efficacy rather than safety, 
and further study has been done to assess specific 
side effects.
Upper GI tract safety
A pooled analysis of upper GI tract safety of   risedronate 
5 mg daily did not show a difference compared to 
placebo even among patients with a higher risk of 
such events.38 This analysis included 9 multicenter, 
double-blind,  randomized,  placebo-controlled  trials 
conducted  between  November  1993  through April 
1998 with 5020 subjects who received risedronate 
5 mg compared to 5048 patients who took placebo. 
At study entry, many subjects had a history of gastro-
intestinal problems in each group (61.1% of placebo 
and 61.0% of risedronate patients). The two groups 
were similar for history of GI disease, active GI tract 
disease, use of antisecretory drugs during the stud-
ies, and use of aspirin or NSAIDS during the studies. 
Following risedronate treatment, the upper GI tract 
adverse event rate was 29.6% in the placebo group 
compared with 29.8% in the   risedronate group, and 
the upper GI tract event rate per 100 patient years was 
19.2 in the placebo group versus 20 in the   risedronate 
group (P = 0.3). Patients on risedronate 5 mg daily 
did not experience worsening of their existing active 
heartburn,  esophagitis,  other  esophageal  disor-
ders, or peptic ulcer disease. Endoscopy performed 
in  349  subjects  did  not  show  statistical  difference 
between the groups.38
A  small  study  looked  at  the  tolerability  of  rise-
dronate specifically for patients who previously had 
been unable to tolerate alendronate due to upper gastro-
intestinal events.39 Sixty-six post-menopausal women 
were  enrolled,  with  35  receiving  risedronate  5  mg 
daily and 31 receiving placebo. In the placebo group, 
5 patients stopped treatment because of gastrointes-
tinal complaints compared with 4 patients from the 
risedronate group (95% CI -29.6% to 17%). The num-
ber of patients who continued to take treatment and 
experienced  adverse  gastrointestinal  events  (19.4% 
placebo, 20.0% risedronate) was considered compa-
rable between the groups (95% CI not provided).
Atypical fracture risk
A US Food and Drug Administration (FDA) Drug 
safety communication on October 13, 2010 identi-
fied the risk of atypical fractures of the thigh, known 
as subtrochanteric and diaphyseal femur fractures, in 
patients who take bisphosphonates for osteoporosis.40 
Diaphyseal femur fractures occur in the long part of 
the thigh bone. These fractures are very   uncommon Gates and Das
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and appear to account for less than 1% of all hip 
and femur fractures in the general population. It is 
not clear if bisphosphonates are the cause in patients 
using these medications.40 According to the Atypical 
  Femoral  Fracture  Task  Force  Report,  the  majority 
(120 of 169) such cases occurred after oral alendronate 
  monotherapy, and 12 patients were treated with oral 
risedronate (of these, one patient received risedronate 
followed by oral alendronate, 2 were treated with alen-
dronate prior to risedronate, and another was treated 
with etidronate prior to risdedronate).41 Median dura-
tion of bisphosphonate treatment was 7 years. The 
task force report concluded that the incidence of atyp-
ical fractures associated with bisphosphonate therapy 
for osteoporosis appears to be very low, particularly 
compared  with  the  number  of  vertebral,  hip,  and 
other fractures that are prevented by bisphosphonates. 
Moreover, a causal association between bisphospho-
nates and atypical fractures has not been established. 
However, recent observations suggest that the risk 
rises with increasing duration of exposure, and there 
is concern that lack of awareness and underreporting 
may mask the true incidence of the problem.41 Given 
the relative rarity of atypical femoral fractures, the 
task force recommends that specific diagnostic and 
procedural codes be created and that an international 
registry be established to facilitate studies of the clini-
cal and genetic risk factors as well as optimal surgical 
and medical management of these fractures.41
Atrial fibrillation
The development of atrial fibrillation following treat-
ment also has been a concern for the bisphosphonates. 
A  pooled  analysis  of  risedronate  phase  3  placebo 
controlled  clinical  trials  evaluated  non-adjudicated 
adverse events of atrial fibrillation, cerebrovascular 
accidents, and death from these events in approxi-
mately 15,000 patients who received treatment for 
about 2 years.42 There was no significant difference 
in the incidence of atrial fibrillation, cerebrovascular 
accidents, and death from these events between rise-
dronate and placebo. However, it may be reasonable 
to use risedronate cautiously in patients who already 
have atrial fibrillation or other cardiac issues.
renal toxicity
The US product label states that risedronate not be 
given to patients with severe renal dysfunction defined 
as creatinine clearance (CrCl) of ,30 mL/min, due 
to  lack  of  prospective  efficacy  and  safety  data  in 
this  population.13  A  pooled  retrospective  analysis 
included  9  double-blind,  randomized,  placebo-con-
trolled phase III studies in patients who received rise-
dronate 5 mg or placebo for an average exposure of   
2 years duration. Adverse events related to renal func-
tion  were  similar  between  the  risedronate  and  pla-
cebo groups in all renal impairment subgroups: mild 
(CrCl $ 50 and ,80 mL/min), moderate (CrCl $ 30 
and ,50 mL/min) and severe (CrCl , 30 mL/min).43
Osteonecrosis of the Jaw
Osteonecrosis of the jaw (ONJ) has been linked to 
high-dose  intravenous  bisphosphonate  use  in  bone 
cancers, but ONJ has also been observed at a much 
lower incidence in patients on oral bisphosphonates 
taken for osteoporosis.44 According to the American 
Dental Association Expert Panel opinion, the risk of 
ONJ with bisphosphonate therapy is very low, with 
approximately  0.7  per  100,000  person-years  expo-
sure to alendronate. Other nitrogen-containing oral 
bisphosphonates, such as risedronate, are expected 
to have similar risk.45 The US prescribing informa-
tion for risedronate states that discontinuation of the 
medication for patients requiring invasive dental pro-
cedures may reduce the risk of ONJ.13 The American 
Association of Maxillofacial Surgeons has published 
a position paper that provides further guidance for 
bisphosphonates regarding dental procedures.46 For 
individuals who have taken an oral bisphosphonate 
for less than three years and have no clinical risk fac-
tors, no alteration or delay in the planned surgery is 
recommended. For those patients who have taken an 
oral bisphosphonate for more than three years with 
or without any concomitant prednisone or other ste-
roid medication, the prescribing provider should be 
contacted to consider discontinuation of the oral bis-
phosphonate for three months prior to oral surgery. If 
possible, the bisphosphonate should not be restarted 
until osseous healing has occurred.
Cancer risk
There has been concern regarding possible risk of 
esophageal cancer with bisphosphonates. The larg-
est review of this to date utilized the UK General 
Practice Research Database to compare cancer rates 
in patients taking bisphosphonates with nonusers.47 risedronate for hip fracture
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2012:5  9
In each group 41,826 records were included. In the 
bisphosphonate  group  37  gastric  cancers  and  79 
esophageal cancers occurred compared with 43 gas-
tric cancers and 72 esophageal cancers in the nonuser 
group, which was not significantly different (adjusted 
hazard ratio for combined outcome 0.96 [95% CI, 
0.74–1.25]). Esophageal cancers alone also did not 
reach statistical significance (adjusted hazard ratio, 
1.07  [95%  CI,  0.77–1.49]).    Therefore,  cancer  risk 
alone does not appear to be a reason to withhold bis-
phosphonate treatment, but more data is needed for 
patients who have a previous history of gastric or 
other cancers.
Musculoskeletal pain
Concern has also been raised regarding musculosk-
eletal pain caused by the bisphosphonates. A recent 
retrospective analysis of 26,545 US veterans age 65 
and older found no significant relationship between 
bisphosphonate use and the development of musculo-
skeletal pain.48 Data from the original clinical trials of 
the medications (not head-to-head studies of agents) 
indicates that use of IV forms of bisphosphonates may 
be more likely to cause this issue.49 However, because 
this issue could present with similar symptoms to other 
conditions, it is important to consider in a patient tak-
ing risedronate and other bisphosphonates.
Ocular inflammation
Though rare, ocular inflammation has been reported 
in  patients  receiving  bisphosphonates. A  case  report 
in a patient treated with alendronate for 6 months then 
switched to risedronate for 2 months reported bilateral 
anterior uveitis. It resolved after discontinuation of rise-
dronate.50 A review of a large VA database did not show 
a higher rate of uveitis/scleritis in patients treated with 
bisphophonsphonates (RR 1.23, 95% CI 0.85–1.79).51
Dermatologic
Cutaneous adverse events associated with risedronate 
are reported to be rash (1–10 per 1000)/uncommon, 
pruritis (1–10 per 10,000)/rare and urticaria/angioe-
dema/bullous  reactions/photosensitivity  (,1  to  10 
per 10,000)/very rare.52
Hepatitis
A case report has been published in an 81-year-old 
woman  who  developed  hepatitis  after  long  term 
(about 4 years) treatment with risedronate.53 Patient 
was receiving metoprolol, fluvastatin, acetaminophen, 
aspirin and calcium carbonate. Risedronate was dis-
continued and complete liver function was restored 
in about 12 months. Bisphosphonate hepatotoxicity is 
rare but was previously reported with alendronate.54 
The underlying mechanism is unknown.
The  US  FDA  requires  medication  guides  to  be 
issued with all approved prescribed bisphosphonate 
drugs in US. The medication guide includes informa-
tion for patients taking bisphosphonates and identifies 
serious side effects associated with bisphosphonates. 
These include esophagus problems, low calcium lev-
els, severe jaw bone problems (osteonecrosis), bone 
joint or muscle pain, and unusual thigh bone   fractures.55 
Therefore, the US FDA considers the adverse events 
from these medications to be similar, and it is difficult 
to differentiate if one bisphosphonate is less likely to 
cause these issues. The only potential exception is the 
possible greater gastrointestinal tolerability that rise-
dronate may possess compared to alendronate.
patient preference
Though the major studies with risedronate were com-
pleted using a dose of 5 mg daily, patients and pre-
scribers do have other options, as risedronate is also 
available in a once weekly 35 mg dose, a twice per 
month dose of 75 mg (given on consecutive days for a 
total of 150 mg per month) and a single once-monthly 
dose of 150 mg. Less frequent administration may be 
beneficial for some patients, and studies provide lim-
ited data comparing these different risedronate dosage 
forms. Other studies also provide insight into medica-
tion adherence, which is often thought to be a benefit 
to the less frequently administered dosage forms.
Only once-daily risedronate has been studied for its 
ability to reduce fracture, but once-weekly risedronate 
in doses of both 35 mg and 50 mg were compared in 
a non-inferiority study with 5 mg risedronate daily 
based upon effects on lumbar spine BMD.56 This study 
lasted one year and enrolled 1456 post-menopausal 
women 50 years and older. No significant difference 
was found between the groups, and 35 mg was con-
sidered to be the optimal once-weekly dose since there 
was no greater benefit with 50 mg weekly.
Once-monthly risedronate was compared to once-
daily  risedronate  in  a  randomized,  double-blind, 
active-controlled, phase II study.57 This was designed Gates and Das
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primarily to evaluate comparative tolerability between 
doses but evaluated efficacy using BMD and bone turn-
over markers as a secondary endpoint. All patients were 
women aged 50 to 85 years who were 5 or more years 
post-menopausal and had a T-score ,−2.0. The daily 
risedronate dose was 5 mg, and patients taking rise-
dronate once monthly were given doses of 100, 150, or 
200 mg for a total of 6 months. A total of 370 patients 
were enrolled. The 150 and 200 mg monthly doses were 
not significantly different from the 5 mg daily dose for 
either BMD or markers of bone turnover, and all of the 
doses had similar tolerability to the 5 mg daily dose.
Dosage  forms  that  require  less  frequent  admin-
istration  may  be  preferable  for  patients  because  of 
reduced pill burden which potentially could result in 
improved medication adherence. Measures to improve 
adherence may be particularly important for bispho-
sphonates  because  some  data  indicates  that  patient 
adherence with bisphosphonates is poor. In the retro-
spective REALITY study discussed previously, inves-
tigators stopped follow-up if patients were found to 
be non-adherent with the medication (defined as more 
than a 15-day gap between fills).28 Using this criteria, 
only 22% of the original cohort could still be followed 
at 1 year after bisphosphonate initiation, and only 3% 
could be followed after 3 years of treatment.
Studies have also examined the potential impact 
of a lack of adherence. One study enrolled women 
aged 60–78 who continued bisphosphonates for at 
least 2 years.58 Patient data was obtained from a large 
administrative  database,  and  the  records  of  9,063 
women  were  included.  The  majority  were  taking 
alendronate, but 2089 were taking risedronate. For 
women who stopped the medication, the hazard ratio 
for a hip fracture at 90 days after stopping bispho-
sphonate treatment was 1.2 (P = 0.016).   However, 
investigators also measured the medication posses-
sion ratio (MPR), which is a measure of medication 
adherence  based  on  the  percentage  of  medication 
refilled on time. In the subgroup of patients whose 
MPR was $80% for 2 years or longer prior to stop-
ping  the  bisphosphonate,  there  was  no  significant 
difference in the incidence of hip fracture for up to 
9  months  after  stopping  treatment. Another  retro-
spective  study  evaluated  the  relationship  between 
fracture risk and adherence for patients taking either 
risedronate  or  alendronate.59  This  analysis  used  a 
nested case control design with information from a 
large database in Quebec. Patients were included if 
taking alendronate at either 10 mg daily or 70 mg 
weekly or risedronate at either 5 mg daily or 35 mg 
weekly.  Patients  were  considered  to  be  adherent 
for taking 80% or more of the medication. Patients 
whose adherence was ,80% had an adjusted RR for 
hip fracture of 1.28 (95% CI 1.02, 1.61).
Studies  have  also  examined  whether  the  differ-
ent  administration  intervals  could  actually  improve 
adherence. A small study that compared risedronate 
5 mg daily and 35 mg weekly found that the weekly 
regimen  actually  may  be  more  difficult  for  some 
patients to remember.60 In addition to the risedronate 
groups, this study also included a placebo group, and 
41 patients enrolled in each of the 3 groups. In both 
the placebo and risedronate 5 mg group, 2 patients 
were not adherent, but 4 patients were not adherent 
in the 35 mg weekly group. Though this was a pro-
portionately large increase in nonadherence, it did not 
reach statistical significance. However, patients in the 
study reported difficulty with remembering the weekly 
dose. Therefore, patients and prescribers may need to 
discuss if daily or weekly administration will be the 
easiest for a particular patient since available evidence 
shows the two forms will produce an equivalent effect 
on bone density when taken as scheduled.
A retrospective analysis of adherence for patients 
taking ibandronate once monthly compared with those 
taking alendronate or risedronate once weekly was 
conducted in France using a large medical   database.61 
Patients were over 45 years of age, and the analysis 
included 1,001 patients in the once-monthly iban-
dronate group and 1,989 in the   once-weekly group 
(581 taking alendronate and 1408 taking risedronate). 
A Kaplan-Meier analysis found that patients in the 
once-monthly group were significantly more likely 
to be persistent in taking the medication over time 
(P , 0.001). However, the rate of adherence was 
still low in both groups. The unadjusted persistence 
rates at 6 months were 57.3% in the once monthly 
group and 45.7% in the once weekly group, and at 
12 months the persistence rates were 47.5% in the 
monthly group and 30.4% in the weekly group.
place in Therapy
Various international guidelines recommend a wide 
range  of  options  as  potential  first-line  treatments 
for  osteoporosis,  and  a  summary  of  key  points risedronate for hip fracture
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from   international guidance published since 2008 is 
  provided in the table.62–68 However, the guidelines rec-
ommend treatments based on both vertebral and non-
vertebral efficacy, and not all agents have benefit for 
hip   fracture. Some guidelines do make note of those 
medications with documented   benefit for hip fracture, 
and these agents include alendronate, denosumab, rise-
dronate, strontium, and zoledronic acid.63–67   Hormone 
  replacement therapy is also considered to be effective 
for hip fracture, but most guidelines recommend its 
use be limited to post menopausal women who clearly 
need relief from vasomotor symptoms and that it be 
given for the shortest duration possible.63–65 Strontium 
is not mentioned in all guidelines because it is cur-
rently not available in the US and Canada, and guide-
lines note that hip fracture data for strontium was 
provided for a subset of the population rather than 
the whole study population.63,66 Denosumab was not 
available when some of the guidelines were published 
and therefore is not mentioned in all guidelines.
A primary reason that multiple agents are considered 
to be first line is that there are a limited number of   
Table 1. Summary of guidance for osteoporosis treatments
Osteoporosis guidelines/guidance Brief summary of medication recommendations
Author: raef, et al62 
Organization: King Faisal Specialist Hospital  
Osteoporosis working Group 
Year published: 2011
Bisphosphonates are first line and alendronate is preferred 
bisphosphonate; raloxifene and strontium ranelate are second-
line agents; teriparatide may be used second-line for some 
patients; calcitonin should only be used if other agents cannot be.
Author: Body, et al63 
Organization: Belgian Bone Club 
Year published: 2010
Bisphosphonates, SErMs, denosumab, and strontium are 
all potential first-line treatments; states there is insufficient 
evidence to compare bisphosphonates; hormone replacement 
should only be used for women with menopause-related 
symptoms and for the shortest duration possible; teriparatide 
should be reserved for high-risk patients.
Author: North American Menopause Society64 
Organization: North American Menopause Society 
Year published: 2010
Bisphosphonates are first-line treatment; raloxifene can 
be helpful for vertebral fractures but uncertain benefit for 
nonvertebral fractures; teriparatide used for high risk-patients 
for no more than 2 years; estrogen should be used primarily for 
menopause symptoms and must carefully weigh benefit when 
menopause symptoms cease; calcitonin is second line because 
it is less effective than other agents.
Author: papaioannou, et al65 
Organization: Scientific Advisory Council  
of Osteoporosis Canada 
Year published: 2010
risedronate, alendronate, zoledronic acid, denosumab, and 
raloxifene are all considered first-line treatments for post-
menopausal women with osteoporosis, and hormone therapy 
is considered to be a first-line treatment for post-menopausal 
women who are experiencing vasomotor symptoms; etidronate 
and calcitonin are considered to be options for those intolerant 
of first-line treatments.
Author: Compston, et al66 
Organization: National Osteoporosis Guideline  
Group (UK) 
Year published: 2009
Alendronate is first choice due to generic availability; if 
alendronate is not tolerated or is contraindicated, other 
bisphosphonates, strontium ranelate, or raloxifene are options; 
teriparatide should be reserved for those at very high risk 
because of its cost.
Author: Kanis, et al67 
Organization: International Osteoporosis  
Foundation and European Society for Clinical  
and Economic Evaluation of Osteoporosis  
and Osteoarthritis 
Year published: 2008
Multiple agents can be used depending on the needs of the 
patient; alendronate, risedronate, and strontium are the only 
agents considered effective for hip fracture; calcitonin is a 
second-line agent.
Author: Qaseem, et al68 
Organization: American College of physicians 
Year published: 2008
Choice of therapy is recommended to be based on individual 
patient needs; bisphosphonates considered first line because 
of benefit for vertebral, non-vertebral, and hip fractures; many 
other medications considered to have good evidence for 
vertebral fractures.Gates and Das
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studies comparing agents. As some   guidelines note, 
there are no randomized, controlled trials that compare 
agents head-to-head for efficacy. Some retrospective 
studies have been completed, and those involving rise-
dronate were included in the “Head-to-Head   Studies” 
portion of the “Clinical Studies” section of this paper. 
There is also limited data to make full economic com-
parisons of the agents. The largest body of economic 
research has focused on alendronate and risedronate, 
as noted above in the “Cost Effectiveness for Hip Frac-
ture” section. Two guidelines recommend alendronate 
as the first-line treatment, with one of these specifically 
citing alendronate’s generic availability as a benefit.62,66 
Some  guidelines  also  recommend  that  teriparatide 
be reserved for patients at highest risk because of its 
cost.63,66
Based on guidelines, risedronate is one of the first-
line treatments to prevent hip fracture. As noted above, 
comparing  risedronate  against  all  other  treatments 
that can prevent hip fracture is difficult because of 
limited head-to-head data. However, available infor-
mation provides some useful insight when choos-
ing between agents for individual patients. As noted 
previously in the “Head-to-Head Studies” section, 
comparisons  between  risedronate  and  alendronate 
for efficacy and cost effectiveness have had mixed 
results, making it less clear on a population basis if 
one medication is clearly a better choice. However, 
the availability of generic alendronate may be ben-
eficial for patients who are bearing the cost of the 
medication. There is some evidence that risedronate 
may  have  better  GI  tolerability  than  alendronate 
and therefore may be preferred over alendronate for 
some patients. For patients needing an oral medica-
tion who have difficulty with tolerability, strontium 
may be less likely to cause gastrointestinal issues 
than bisphosphonates based on its side effect profile 
from placebo-controlled studies, but it has not been 
compared with bisphosphonates head-to-head. Rise-
dronate’s availability in different oral dosage regi-
mens offers potential options for patients who have 
difficulty with adherence and is a potential advantage 
over medications such as strontium that require daily 
dosing. However, a discussion between a healthcare 
provider and the patient is important to determine if 
less frequent oral administration would be easier or 
more difficult for the patient to remember or if medi-
cations that can be administered directly by healthcare 
providers, such as intravenous bisphosphonates or 
denosumab, may be the best option for adherence. 
At this point there is insufficient data to compare the 
efficacy of oral risedronate to the intravenous bis-
phosphonates, but consideration of the patient’s tol-
erability of an oral versus an intravenous agent is an 
important consideration because there are potential 
differences in side effects between the two dosage 
forms. As noted previously, denosumab may poten-
tially be more cost effective than bisphosphonates 
for patients who have difficulty with adherence,35 but 
this needs further study.
conclusion
Risedronate is an effective treatment for hip fracture 
in postmenopausal women and for some patients may 
have advantages over other bisphosphonates. How-
ever, before initiating treatment with risedronate, it 
is important to carefully evaluate the patient’s need 
and  appropriateness  for  therapy.  Data  from  trials 
indicate  that  risedronate  does  not  have  benefit  for 
hip fracture for patients who are not at risk for frac-
ture, and results show that advanced age alone is not 
a  reason  for  treatment.  Therefore,  careful  evalua-
tion of a patient’s risk for fracture using FRAX or 
other available screening tools is important. Potential 
medication adverse reactions must also be consid-
ered. Risedronate has been tolerated well in clinical 
trials, but an individual patient’s co-morbidities and 
previous  medication  sensitivities  (such  as  gastro-
intestinal  toleration  of  medications)  are  important. 
Serious side effects of risedronate and other bispho-
sphonates are rare but could have significant conse-
quences for some patients with co-morbidities. The 
poor adherence to bisphosphonates found in studies 
may warrant discussion of side effects and patient 
concerns. When patients are appropriately considered 
for treatment, risedronate represents a useful option 
in the prevention of hip fracture in postmenopausal   
women.
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